Dose-escalated radiotherapy in esophageal cancer : A review of the literature
Copyright © 2022 The Author(s). Published by Elsevier Masson SAS.. All rights reserved..
For non-operable, localized esophageal cancer, definitive concurrent chemoradiotherapy is the standard treatment. Currently, the radiation dose recommended is 50 to 50,4Gy. However, the optimal radiation dose remains controversial. Many studies have demonstrated that locoregional failure remains a common failure pattern, most likely to occur within the original gross tumor volume. Several retrospective studies have indicated that higher radiation dose may improve local control and survival while others failed to demonstrate improved oucomes. In three randomized trials (INT0123, ARTDECO, and CONCORDE), dose escalation did not improve locoregional control nor survival, establishing 50Gy as the standard chemoradiation dose for patients who will not undergo surgery. Here, we reviewed the results of dose escalation in the literature in the neoadjuvant and definitive settings.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:26 |
|---|---|
| Enthalten in: |
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique - 26(2022), 6-7 vom: 09. Okt., Seite 884-889 |
| Sprache: |
Französisch |
|---|
| Weiterer Titel: |
Escalade de dose dans les cancers de l’œsophage : revue de la littérature |
|---|
| Beteiligte Personen: |
Boustani, J [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Cancer de l’œsophage |
|---|
| Anmerkungen: |
Date Completed 20.09.2022 Date Revised 20.09.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.canrad.2022.06.021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM345266633 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM345266633 | ||
| 003 | DE-627 | ||
| 005 | 20231226024656.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||fre c | ||
| 024 | 7 | |a 10.1016/j.canrad.2022.06.021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1150.xml |
| 035 | |a (DE-627)NLM345266633 | ||
| 035 | |a (NLM)36008261 | ||
| 035 | |a (PII)S1278-3218(22)00127-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a fre | ||
| 100 | 1 | |a Boustani, J |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Dose-escalated radiotherapy in esophageal cancer |b A review of the literature |
| 246 | 3 | 3 | |a Escalade de dose dans les cancers de l’œsophage : revue de la littérature |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.09.2022 | ||
| 500 | |a Date Revised 20.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 The Author(s). Published by Elsevier Masson SAS.. All rights reserved. | ||
| 520 | |a For non-operable, localized esophageal cancer, definitive concurrent chemoradiotherapy is the standard treatment. Currently, the radiation dose recommended is 50 to 50,4Gy. However, the optimal radiation dose remains controversial. Many studies have demonstrated that locoregional failure remains a common failure pattern, most likely to occur within the original gross tumor volume. Several retrospective studies have indicated that higher radiation dose may improve local control and survival while others failed to demonstrate improved oucomes. In three randomized trials (INT0123, ARTDECO, and CONCORDE), dose escalation did not improve locoregional control nor survival, establishing 50Gy as the standard chemoradiation dose for patients who will not undergo surgery. Here, we reviewed the results of dose escalation in the literature in the neoadjuvant and definitive settings | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Cancer de l’œsophage | |
| 650 | 4 | |a Chemoradiation | |
| 650 | 4 | |a Chimioradiothérapie | |
| 650 | 4 | |a Contrôle locorégional | |
| 650 | 4 | |a Dose-escalation | |
| 650 | 4 | |a Escalade de dose | |
| 650 | 4 | |a Esophageal cancer | |
| 650 | 4 | |a Locoregional control | |
| 700 | 1 | |a Créhange, G |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique |d 1998 |g 26(2022), 6-7 vom: 09. Okt., Seite 884-889 |w (DE-627)NLM092193420 |x 1769-6658 |7 nnns |
| 773 | 1 | 8 | |g volume:26 |g year:2022 |g number:6-7 |g day:09 |g month:10 |g pages:884-889 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canrad.2022.06.021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 26 |j 2022 |e 6-7 |b 09 |c 10 |h 884-889 | ||